Piper Sandler initiated coverage of RxSight (RXST) with a Neutral rating and $18 price target The firm likes the company’s novel light ...

RxSight (NASDAQ:RXST), a maker of light-adjustable intraocular lenses, fell ~28% in the premarket after the company slashed its full-year guidance and announced lower-than-expected preliminary revenue ...

RxSight projects the sale of 27,579 Light Adjustable Lenses (LAL/LAL+), with a growth of 36%Y/Y increase in procedure volume. Also, the company anticipates the s ALISO VIEJO, Calif., April 02 ...

Ron Kurtz, Chief Executive Officer and President of RxSight, said, “Given RxSight’s more significant installed base of surgeons and practices, we now must navigate headwinds affecting the overall ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $36.5, a high estimate of $66.00, and a low estimate of $17.00. Experiencing a 18.74% decline, ...

The RxSight ® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens ® (LAL™/LAL+ ®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first ...

The sale of 27,579 Light Adjustable Lenses (LAL™/LAL+ ®); representing a 36% increase in procedure volume compared to the first quarter of 2024; and The sale of 73 Light Delivery Devices (LDD ...

RxSight projects the sale of 27,579 Light Adjustable Lenses (LAL/LAL+), with a growth of 36%Y/Y increase in procedure volume. Also, the company anticipates the sale of 73 Light Delivery Devices ...